Evaluation of Serologic Marker Tests for Hepatitis B Viral Infection Using the Automated Immunoassay System ARCHITECT i2000.
- Author:
Sean Mi SONG
1
;
Won Il OH
;
Dae Won KIM
Author Information
1. Department of Clinical Pathology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea. wioh@smc.samsung.co.kr
- Publication Type:Original Article
- Keywords:
ARCHITECT i2000;
Chemiluminescent microparticle immunoassay;
HBs antigen;
anti-HBs;
anti-HBc
- MeSH:
Hepatitis B virus;
Hepatitis B*;
Hepatitis*;
Humans;
Immunoassay*;
Korea;
Prevalence;
Sensitivity and Specificity
- From:Korean Journal of Clinical Pathology
2002;22(1):42-46
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The prevalence of Hepatitis B virus (HBV) in Korea is still higher than that of devel-oped countries. Recently, the automated chemiluminescent microparticle immunoassay analyzer ARCHITECT i2000 (Abbott Laboratories, Abbott Park, IL USA) was introduced in Korea and we evaluated performance of the tests for serological markers for HBV infection. METHODS: We analyzed precision, agreement, sensitivity, specificity and throughput of the HBs antigen, anti-HBs and anti-HBc as well as linearity and compared with the AxSYM (Abbott Labora-tories, Abbott Park, IL USA) for anti-HBs. Precision, linearity and comparison were performed on the basis of the National Committee for Clinical Laboratory Standards guidelines. Random patients 'sera were used for this study. RESULTS: The coefficients of variations of precision were below 5% for anti-HBs and anti-HBc (total) except for the HBs antigen. The agreements, sensitivities and specificities for serologic mark-ers were more than 90%. The linearity and comparison for anti-HBs were statistically significant (P < 0.001). The throughput of ARCHITECT i2000 was 110 tests/hours and that was 2.8 times faster than that of the AxSYM. CONCLUSIONS: These results suggest that ARCHITECT i2000 can provide rapid and effective results for serologic markers for HBV infection. However, each laboratory should decide the utiliza-tion of this analyzer on the basis of volume of samples, other items tested concurrently, and the inter-face of existing facilities etc.
